WallStreetZenWallStreetZen

NASDAQ: ACB
Aurora Cannabis Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ACB stock forecasts and price targets.

Forecast return on equity

Is ACB forecast to generate an efficient return?

Company
5.03%
Industry
30.12%
Market
90.06%
ACB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACB forecast to generate an efficient return on assets?

Company
3.34%
Industry
15.06%
ACB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACB earnings per share forecast

What is ACB's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$0.56+1,882.14%
Avg 2 year Forecast
$0.17+507.14%
Avg 3 year Forecast
$0.37+1,221.43%
ACB's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ACB revenue forecast

What is ACB's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$272.1M+14.15%
Avg 2 year Forecast
$296.4M+24.34%
Avg 3 year Forecast
$329.1M+38.06%
ACB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ACB earnings growth forecast

How is ACB forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
108.71%
Industry
26.57%
Market
15.81%
ACB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ACB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ACB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ACB revenue growth forecast

How is ACB forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
9.34%
Industry
4.17%
Market
10.24%
ACB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ACB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ACB vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ACB$4.30N/AN/A
TKNO$4.93N/AN/A
CGC$1.13N/AN/A
ESPR$1.00$6.20+520.00%Buy
LFCR$7.96$6.00-24.62%Hold
View Top Pharmaceutical Stocks

Aurora Cannabis Stock Forecast FAQ

What is ACB's earnings growth forecast for 2026-2028?

(NASDAQ: ACB) Aurora Cannabis's forecast annual earnings growth rate of 108.71% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 26.57%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.81%.

Aurora Cannabis's earnings in 2025 is $172,992.On average, 2 Wall Street analysts forecast ACB's earnings for 2026 to be $31,209,998, with the lowest ACB earnings forecast at -$8,435,135, and the highest ACB earnings forecast at $70,855,131. On average, 1 Wall Street analyst forecast ACB's earnings for 2027 to be $9,559,819, with the lowest ACB earnings forecast at $9,559,819, and the highest ACB earnings forecast at $9,559,819.

In 2028, ACB is forecast to generate $20,806,665 in earnings, with the lowest earnings forecast at $20,806,665 and the highest earnings forecast at $20,806,665.

If you're new to stock investing, here's how to buy Aurora Cannabis stock.

What is ACB's revenue growth forecast for 2026-2028?

(NASDAQ: ACB) Aurora Cannabis's forecast annual revenue growth rate of 9.34% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.24%.

Aurora Cannabis's revenue in 2025 is $250,578,832.On average, 3 Wall Street analysts forecast ACB's revenue for 2026 to be $15,303,752,327, with the lowest ACB revenue forecast at $14,687,818,795, and the highest ACB revenue forecast at $16,223,575,644. On average, 1 Wall Street analysts forecast ACB's revenue for 2027 to be $16,668,950,753, with the lowest ACB revenue forecast at $16,668,950,753, and the highest ACB revenue forecast at $16,668,950,753.

In 2028, ACB is forecast to generate $18,508,372,449 in revenue, with the lowest revenue forecast at $18,508,372,449 and the highest revenue forecast at $18,508,372,449.

What is ACB's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: ACB) forecast ROA is 3.34%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.06%.

What is ACB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ACB) Aurora Cannabis's current Earnings Per Share (EPS) is $0.03. On average, analysts forecast that ACB's EPS will be $0.56 for 2026, with the lowest EPS forecast at -$0.15, and the highest EPS forecast at $1.26. On average, analysts forecast that ACB's EPS will be $0.17 for 2027, with the lowest EPS forecast at $0.17, and the highest EPS forecast at $0.17. In 2028, ACB's EPS is forecast to hit $0.37 (min: $0.37, max: $0.37).

What is ACB's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: ACB) forecast ROE is 5.03%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.